Evidence of deliberate climate damage
A new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
New polymer can stop biofilm formation
British researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters
Rewind Therapeutics extends Series A financing
With Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
Henkel buys FDCA from Avantium NV
Bioplastics specialist Avantium N.V. has inked a 5-year agreement to supply Henkel with plant sugar based furandicarboxylic acid , a building block of PEF bioplastics.
Vésale Bioscience wins R&D grant
Phage therapy specialist Vésale Bioscience gas bageds 1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).
Abionyx Pharma announces success in fighting sepsis-triggered AKI
Abionyx Pharma SA has announced positive data from Phase IIa testing of iCER-001, a recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI)
BioNTech bags Instadeep for £562m
BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
Roche withdraws checkpoint blocker from the market
Roche AGs US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the help of a 25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
Hummingbird and Synaffix in $150m ADC deal
Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.